



Date: January 18, 2024

To The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra – Kurla Complex Bandra (East) <u>Mumbai – 400 051</u> Stock Code : INDOCO-EQ	To The Listing Department Bombay Stock Exchange Limited Floor 25, P. J. Towers, Dalal Street, <u>Mumbai – 400 001</u> Stock Code : 532612
---	---

Dear Sir/Madam,

Sub: Receipt of Establishment Inspection Report by Indoco Remedies Limited - Closure of USFDA Inspection of Goa Plant-I

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and further to our intimation dated October 19, 2023 about the pre-approval inspection (“PAI”) conducted for the two drug product applications (ANDAs), by the United States Food and Drug Administration (“USFDA”) at the Company’s Solid Oral Formulation facility (Plant I) located at Goa (“Facility”) from October 12, 2023 to October 18, 2023, we hereby further inform you that the Company had addressed the said observations comprehensively within the stipulated time, and has received Establishment Inspection Report (EIR) from USFDA, indicating successful closure of the said inspection.

The PAI was conducted for two drug product applications (ANDAs) filed from this Facility, for which approvals are expected soon.

Please find enclosed herewith press release in this regard. Kindly take the above information on record.

**Thanking you,
Yours faithfully,
For Indoco Remedies Limited**

**RAMANATHA
N HARIHARAN**

Digitally signed by
RAMANATHAN HARIHARAN
Date: 2024.01.18 13:58:11
+05'30'



**Ramanathan Hariharan
Company Secretary & Head- Legal**



PRESS RELEASE

Receipt of Establishment Inspection Report by Indoco Remedies Limited - Closure of USFDA Inspection of Goa Plant-I

Mumbai, January 18, 2024: Indoco Remedies Limited has received the Establishment Inspection Report (EIR) from the U.S. FDA for the Pre-Approval Inspection (PAI) conducted for the oral dosage form at the manufacturing facility located at Goa Plant-I, L-14 Verna Industrial Area Verna, Goa, 403722, India, in October 2023. The Company had addressed the observations comprehensively and within the stipulated time. The receipt of the Establishment Inspection Report (EIR) indicates a successful closure of the inspection.

The PAI was conducted for two drug product applications (ANDAs) filed from this facility, for which approvals are expected soon.

Commenting on this development, **Ms. Aditi Panandikar, Managing Director, Indoco Remedies** said, “We stay committed to enabling affordable access to our high-quality products for patients in the US and around the world. This is a testament to our commitment to global standards of Quality and Compliance.”

About Indoco Remedies Limited:

Indoco is a fully integrated, research-oriented pharmaceutical company with presence in 55 countries. The Company's turnover is US\$ 200 million with a human capital of 6000 employees, including over 300 skilled scientists and Field Staff who are the strength of the organization.

The Company has 9 manufacturing facilities, 6 for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 109 million prescriptions annually from over 3,00,000 doctors belonging to various specialties. Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infective, Stomatologicals, Ophthalmic, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management, Gyneacology etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensoform, Sensodent-KF, Aloja, Glychek, Kidodent, Subitral, Rexidin, MCBM 69, Methycal, Dropizine, Noxa, Homide, Cal-Aid, etc. On the international front, Indoco has tie-ups with large generic companies across the globe.

For more details on Indoco, you may visit www.indoco.com

For Media Inquiries Please Contact:

Pramod Ghorpade | Mobile: 9619883225

E-mail: pramod.ghorpade@indoco.com / corpcom@indoco.com